IBC’s 3rd European Protein Kinase Targets, Amsterdam, The Netherlands
Event Nov 03
Protein Kinases are the second largest group of drug targets, after GPCRs, and account for 20-30% of the drug discovery programmes of many companies. With several protein kinase inhibitors already approved for clinical use (Gleever, Iressa, Fasudil) and many more undergoing human clinical trials, kinases offer an exciting therapeutic potential to target serious disease groups, including Cancer, Neurodegenerative and Metabolic diseases.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019